Evidence map›Paper›PMID 29256039›Full record

ReviewJournal of neurovirology2018

When do models of NeuroAIDS faithfully imitate "the real thing"?

Benjamin B Gelman, Janice Endsley, Dennis Kolson

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of neurovirology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Drug discovery today. Disease models · 2020
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Benjamin B GelmanDepartment of Pathology, Route 0419, University of Texas Medical Branch, Galveston, TX, 77555-0419, USA. bgelman@utmb.edu.
Janice EndsleyDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Dennis KolsonDepartment of Neurology, University of Pennsylvania, Philadelphia, PA, 19104-6140, USA.
The University of Texas Medical Branch at Galveston · USUniversity of Pennsylvania · US

Funding

ZOLLINGER-ELLISON SYNDROME AND DUODONAL ULCER DISEASEM01RR000073 · NCRR · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI RAJI, MUKAILA A · 1985 to 2009
$31.3M
Texas NeuroAIDS Research CenterU24MH100930 · NIMH · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GELMAN, BENJAMIN B. · 2013 to 2023
$12.1M
Pathways of HIV neurodegeneration and dimethyl fumarate (DMF/MMF) neuroprotectionR01MH095671 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI ALDOVINI, ANNA, KOLSON, DENNIS LARRY · 2011 to 2015
$3.5M
Regulation of Heme Oxygenase in HIV/HAND PathogenesisR01MH111389 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI KOLSON, DENNIS LARRY · 2016 to 2020
$2.9M
Oxidative Stress, Immune Activation, and Therapeutic Targeting in HIV/HANDR01MH104134 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI KOLSON, DENNIS LARRY · 2014 to 2018
$2.3M
HIV-induced Defects in Pulmonary Macrophages Exacerbate Mycobacterium Tuberculosis Co-infectionR01HL129881 · NHLBI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI ENDSLEY, JANICE J, GELMAN, BENJAMIN B. · 2016 to 2018
$2.1M
The Synaptic Protein Economy in HIV/AIDR01NS072005 · NINDS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GELMAN, BENJAMIN B. · 2010 to 2014
$1.9M
Integrated HIV DNA in CNS and Deep Body CompartmentsR01MH101017 · NIMH · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GELMAN, BENJAMIN B. · 2013 to 2017
$1.4M
NCRR NIH HHS M01 RR000073NIH HHS R01HL129881NIH HHS R01MH101017NIH HHS R01MH104134NIH HHS U24MH100930NIMH NIH HHS R01 MH095671NIMH NIH HHS R01 MH104134NIMH NIH HHS R01 MH111389NIMH NIH HHS U24 MH100930NINDS NIH HHS R01 NS072005
6 · The paper itself

Abstract

HIV-infected patients treated with antiretroviral medicines (ART) still face neurological challenges. HIV-associated neurocognitive disturbances (HAND) can occur, and latent viral DNA persisting in the central nervous system (CNS) prevents eradication of HIV. This communication focuses on how to develop experimental models of HAND and CNS HIV latency that best imitate the CNS pathophysiology in diseased humans, which we take to be "the real thing." Models of HIV encephalitis (HIVE) with active CNS viral replication were developed in the early years of the AIDS pandemic. The clinical relevancy of such models is in sharp decline because HIVE seldom occurs in virally suppressed patients, while HAND remains common. The search for improved models of HAND should incorporate the neurochemical, neuroimmunological and neuropathological features of virally suppressed patients. Common anomalies in these patients as established in autopsy brain specimens include brain endothelial cell activation and neurochemical imbalances of synaptic transmission; classical neurodegeneration may not be as crucial. With regard to latent HIV with viral suppression, human brain specimens show that the pool of latent proviral HIV DNA in the CNS is relatively small relative to the total body pool and does not change substantially over years. The CNS pool of latent virus probably differs from lymphoid tissues, because the mononuclear phagocyte system sustains productive infection (versus lymphocytes). These and yet-to-be discovered aspects of the human CNS of virally suppressed patients need to be better defined and addressed in experimental models. To maintain clinical relevancy, models of HAND and viral latency should faithfully emulate "the real thing."

Indexed as

AIDS Dementia ComplexAnimalsAntigens, CDAntigens, Differentiation, MyelomonocyticAntiretroviral Therapy, Highly ActiveAntiviral AgentsBiomarkersBrainCD163 AntigenCentral Nervous SystemCognitive DysfunctionCytokinesDisease Models, AnimalHIV-1HumansNeurotransmitter AgentsAntigens, CDAntigens, Differentiation, MyelomonocyticAntiviral AgentsBiomarkersCD163 AntigenCytokinesISG15 protein, humanNeurotransmitter AgentsPECAM1 protein, humanPlatelet Endothelial Cell Adhesion Molecule-1Receptors, Cell SurfaceUbiquitinsARTCNSDementiaEradicationHANDHIVLatency

Identifiers

PMID29256039
PMCPMC5910470
OpenAlexW2779164613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.